Table 2.

OR (95% CI) for prostate cancer associated with genetic polymorphisms in GST and NQO1 genes in the EPIC-Heidelberg nested case-control study (n = 740)

GenotypeAllCases (%)Controls (%)OR* (95% CI)
GSTM1
    pres/pres6619 (7.7)47 (9.6)1.00
    pres/del277103 (41.5)174 (35.4)1.43 (0.80-2.55)
    del/del396126 (50.8)270 (55.0)1.15 (0.65-2.04)
    HWE0.080.02
GSTT1
    pres/pres25188 (35.5)163 (33.1)1.00
    pres/del368116 (46.8)252 (51.2)0.87 (0.62-1.22)
    del/del12144 (17.7)77 (15.7)1.08 (0.69-1.69)
    HWE0.470.21
GSTM1/GSTT1
    0 or 1 del14454 (21.8)90 (18.3)1.00
    2 del29892 (37.1)206 (42.0)0.76 (0.51-1.15)
    3 or 4 del297102 (41.1)195 (39.7)0.89 (0.59-1.35)
GSTP1 (A313G)
    AA341125 (50.4)216 (43.9)1.00
    AG32395 (38.3)228 (46.3)0.72 (0.52-1.01)
    GG7628 (11.3)48 (9.8)1.00 (0.60-1.69)
    HWE0.970.28
GSTA1 (G-52A)
    GG21668 (27.4)148 (30.1)1.00
    GA379132 (53.2)247 (50.2)1.16 (0.81-1.64)
    AA14548 (19.4)97 (19.7)1.08 (0.68-1.70)
    HWE0.360.74
NQO1 (C609T)
    CC496163 (65.7)333 (67.7)1.00
    CT21380 (32.3)133 (27.0)1.25 (0.89-1.75)
    TT315 (2.0)26 (5.3)0.41 (0.16-1.06)
    HWE0.190.01

Abbreviation: HWE, Hardy-Weinberg equilibrium.

  • *Conditional logistic regression stratified by case set.

  • P value of χ2 test.